Estrogen Receptor-Positive (ER+) Breast Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 33965
Special Issue Editors
Interests: early breast cancer; adjuvant chemotherapy; chemotherapy for metastatic breast cancer; clinical trials; mTOR inhibitors; CDK4/6 inhibitors; endocrine therapy
Special Issues, Collections and Topics in MDPI journals
Interests: biology of early breast cancer; clinical trials; circulating tumor cells; adjuvant chemotherapy; chemotherapy for metastatic breast cancer; endocrine resistance; mTOR inhibitors; CDK4/6 inhibitors
Special Issues, Collections and Topics in MDPI journals
Interests: breast cancer; cancer of unknown primary; cancer and pregnancy; cancer education
Special Issue Information
Dear Colleagues,
The majority of breast cancers express estrogen and/or progesterone receptors (ER and PR). ER is the primary transcription factor driving oncogenesis in hormone receptor-positive (HR+) breast cancer; it is both the predictor and the target of response to antiestrogen therapy. In tumors without concomitant HER2 amplification, endocrine therapy, aimed at the therapeutic blockade of ER signaling, forms the backbone of treatment for all disease stages; adjuvant endocrine therapy alone reduces the relative risk of recurrence by nearly 40%. Endocrine therapies include aromatase inhibitors (AIs), gonadotropin-releasing hormone (GnRH) agonists, selective ER modulators (SERMs), and selective ER downregulators (SERDs). Despite its wide therapeutic efficacy, endocrine therapy eventually fails in the majority of patients with metastatic and in a proportion of patients with ER+, HER2- early breast cancer who develop endocrine resistance, resulting in disease recurrence. A number of resistance mechanisms can lead to estrogen-independent growth of HR+ breast cancer as a result of genetic and epigenetic alterations, which could be exploited as novel therapeutic targets. This Special Issue focuses on the biology of ER and the implications of ESR1 mutations in HR+ breast cancer, the role of neoadjuvant therapy, the use of multigene assays to select treatment for early disease, the optimal management of premenopausal patients with ER+ breast cancer, the role of extended adjuvant endocrine therapy, the molecular mechanisms mediating endocrine resistance emphasizing the prominent role of the PI3K/Akt/mTOR and CDK4/6/retinoblastoma protein pathways in cancer cell growth and survival, the molecularly targeted agents to overcome or delay endocrine resistance, and potential predictive biomarkers for accurate patient stratification.
Prof. Dr. Christos Papadimitriou
Prof. Dr. Dimitrios Mavroudis
Prof. Dr. Nicholas Pavlidis
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ER+ and/or PR+ breast cancer
- endocrine therapy
- neoadjuvant therapy
- adjuvant chemotherapy
- gene expression assays
- chemotherapy for metastatic breast cancer
- endocrine resistance
- mTOR inhibitors
- CDK4/6 inhibitors
- PI3K inhibitors
- AKT inhibitors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.